Overview

Pramlintide Combined With Model Predictive Control Algorithm

Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is a scientific research study that will look at how a "closed-loop" system and the drug Pramlintide may work together to improve blood sugar control in people with type 1 diabetes mellitus. Pramlintide is approved by the Food and Drug Administration (FDA) and is given as an injection (subcutaneous) that works with insulin to lower blood sugar.
Phase:
N/A
Details
Lead Sponsor:
University of Virginia
Collaborators:
The Paul Manning Foundation
The Paul Manning Foundation (private)
Treatments:
Islet Amyloid Polypeptide
Pramlintide